HIMS-Novo Wegovy Deal Triggers Bullish Analyst Revisions
TL;DR Summary
Hims & Hers jumped about 49% after announcing a deal to offer Novo Nordisk’s Wegovy and Ozempic on its telehealth platform, a move that reduces legal risk as Novo dropped its lawsuit. Analysts at Citi, Deutsche Bank, Bank of America, and Needham issued more favorable views and higher price targets (up to about $30), signaling optimism that the partnership could unlock significant new revenue from official doses. TipRanks shows a Moderate Buy consensus with upside to current levels.
- HIMS-Novo ‘Can’t Quit Each Other’ – Analysts Bullish on Wegovy Deal TipRanks
- Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit Reuters
- Hims & Hers (HIMS) Soars 10.3% on Analyst Upgrades, New Deal Yahoo Finance
- Does This Deal Make Novo Nordisk Stock a Buy? The Motley Fool
- Novo and Hims End Feud, Will Sell Obesity Drugs Together Bloomberg
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
16 min
vs 17 min read
Condensed
98%
3,244 → 78 words
Want the full story? Read the original article
Read on TipRanks